We all know that health spending in the United States has grown, a more interesting question is why, as the answer to that question will help design initiatives to control spending growth. Research published in Health Affairs examines factors in health spending growth over the period 1987 to 2009 for both the Medicare and Commercial populations. (HA Article) The authors begin by noting that early working looking at cost rises from 1940 to the 1990s noted demand side factors like a phenomenal growth in the number of people with insurance, health technology advances and income growth. From 1987 to 2009, however, there was little change in the number of people with coverage and some recent research suggest lower correlation between income and health spending. The authors focus on two factors, the prevalence of treated disease, which may include over-diagnosis, and the increase in spending per treated case. Note that the authors’ analysis is not per capita, but total health spending oriented and is based on survey data. And while the authors try to hold spending constant for inflation, they do not appear to discriminate between the unit price and the utilization components of spending per case. The study finds that about 51% of the spending increase is due to higher treated disease prevalence and about 39% to higher spending per case, thus accounting for almost all of the increase. For Medicare, 78% is due to greater disease prevalence and 14% to higher per case spending, while for commercial insurance the figures are 33.5% and 54%. This reflects the ability of Medicare to control reimbursement by fiat, while private payers are likely doing a good job on utilization control but losing pricing leverage vis-a-vis providers. A number of common diseases account for much of disease prevalence growth and obesity is said to be responsible for 22% of the spending increase. As the authors point out, strategies to reduce spending need to be heavily focused on these aspects of spending growth.
Reasons for Health Spending Growth
By Kevin RocheMay 23, 2013May 24th, 2013Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…